Corticobasal syndrome (CBS) is a progressive neurodegenerative disorder characterized by asymmetric cortical and basal ganglia dysfunction. The syndrome results from the degeneration of specific neuronal populations in the cerebral cortex and basal ganglia, leading to a combination of motor, sensory, cognitive, and behavioral deficits. Understanding which neurons are affected provides insight into disease mechanisms and helps distinguish CBS from related disorders like progressive supranuclear palsy and Parkinson's disease.
| Property |
Value |
| Category |
Atypical parkinsonism |
| Species |
Human |
| Brain Regions |
Motor cortex, basal ganglia, substantia nigra, thalamus |
| Neurotransmitters |
Dopamine, GABA, glutamate, acetylcholine |
| Inheritance |
Mostly sporadic, some genetic forms |
The primary motor cortex (M1) shows significant involvement:
Betz cells (Layer V)
- Large pyramidal neurons
- Corticospinal tract projection
- Severe degeneration in CBS
- Leads to contralateral weakness and apraxia
Layer III pyramidal neurons
- Corticocortical projections
- Involvement correlates with cortical signs
- Contribution to alien limb phenomena
Striatal medium spiny neurons (MSNs)
- Both D1 (direct) and D2 (indirect) pathway neurons
- GABAergic output to globus pallidus
- Dysfunction leads to parkinsonism
- Rigidity and bradykinesia mechanisms
Globus pallidus internus (GPi) neurons
- Major output nucleus of basal ganglia
- Excessive inhibitory output
- Contributes to akinesia
- DBS target in CBS
Substantia nigra pars compacta (SNc)
- Dopaminergic neuron loss (moderate, ~50%)
- Less severe than in PD
- Contributes to parkinsonian features
Motor thalamic nuclei (VLa, VLp)
- Input from basal ganglia output
- Output to motor cortex
- Cerebellar input integration
- Tremor generation
Centromedian nucleus
- Intralaminar thalamic nuclei
- Attention and arousal
- Sleep disturbance correlation
Tau pathology
- 4R tau (paired helical filaments)
- Astroglial plaques
- Tufted astrocytes
- Ballooned neurons (chromatolytic)
Co-pathologies
- AD co-pathology in ~25% of cases
- Lewy bodies in ~20%
- TDP-43 in some cases
Asymmetric involvement
- Contralateral to most affected side
- Motor cortex > premotor cortex
- Basal ganglia involvement
Progression
- Begins in one hemisphere
- Spreads to ipsilateral structures
-eventually bilateral
Akinesia and bradykinesia
- Reduced spontaneous movement
- Slowed voluntary movements
- Fatigue with repeated movements
Rigidity
- Lead-pipe quality
- Cogwheeling may be present
- Axial and limb involvement
Dystonia
- Often focal and action-specific
- Myoclonus may coexist
- Painful posturing
Myoclonus
- Cortical origin (refractory)
- Stimulus-sensitive
- Action-induced
Apraxia
- Ideomotor apraxia most common
- Contralesional to dominant hemisphere
- Impaired tool use
Alien limb syndrome
- Feeling of foreign limb
- Intermanual conflict
- Posterior cortical variant
Cortical sensory loss
- Astereognosis
- Two-point discrimination loss
- Graphesthesia impairment
¶ Cognitive and Behavioral Features
Executive dysfunction
- Working memory impairment
- Set-shifting deficits
- Planning and organization
Language deficits
- Non-fluent aphasia variant
- Phonologic errors
- Reduced verbal fluency
Behavioral changes
- Apathy
- Disinhibition
- Irritability
Distinguishing features
- Vertical supranuclear gaze palsy
- Early falls
- Midline involvement
- Square wave jerks
Distinguishing features
- Tremor predominance
- Levodopa responsiveness
- Symmetric onset
- Lewy body pathology
Distinguishing features
- Memory impairment predominant
- Posterior cortical atrophy pattern
- Amyloid pathology
- Less motor involvement
MRI findings
- Asymmetric cortical atrophy
- Parietal lobe involvement
- "Hummingbird" sign may be absent
- Midbrain atrophy (less than PSP)
FDG-PET
- Hypometabolism in posterior frontal/parietal cortex
- Asymmetric pattern
- Thalamic hypometabolism
CSF
- Elevated tau (total and phosphorylated)
- Reduced Aβ42 in co-pathology
- Neurofilament light chain (NFL)
Blood
- Neurofilament light chain
- GFAP
Parkinsonism
- Limited levodopa response
- Dopamine agonists: Modest benefit
- Amantadine: May help myoclonus
Myoclonus
- Clonazepam
- Valproic acid
- Piracetam
Dystonia
- Botulinum toxin injections
- Muscle relaxants
Physical therapy
- Gait training
- Balance exercises
- Stretching for dystonia
Occupational therapy
- Adaptive equipment
- Home modifications
- Apraxia compensation
Deep brain stimulation
- GPi target
- Mixed results in CBS
- May help rigidity/dystonia
- Tau-targeted therapies
- Biomarker development
- Understanding asymmetric degeneration
- Neuroprotective strategies
- Corticobasal syndrome: Neuronal vulnerability patterns (2020)
- Tau pathology in CBS: 4R tau deposition (2019)
- Motor cortex degeneration in CBS (2021)
- Basal ganglia involvement in corticobasal syndrome (2018)
- Clinical features distinguishing CBS from PSP (2020)
- Apraxia in corticobasal syndrome (2019)
- Myoclonus in CBS: Mechanisms and treatment (2021)
- Neuroimaging biomarkers for CBS (2022)
- DBS outcomes in corticobasal syndrome (2020)
- Tau-targeted therapies in CBS (2022)